drugset / Trial / NCT00869973

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

NCT00869973

Phase 3 Terminated 580 enrolled S. Maria Hospital, Terni
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to compare efficacy and tolerability of aprepitant versus dexamethasone in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide plus anthracyclines) in breast cancer patients.

Timeline

Start
2009-09
Primary completion
2012-07
Completion
2012-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 80 mg Oral
Comparator Dexamethasone Small molecule 4 mg Oral

Indications

No indication recorded.